These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
180 related articles for article (PubMed ID: 23150210)
1. Synthesis and quantitative structure-activity relationships of selective BCRP inhibitors. Marighetti F; Steggemann K; Hanl M; Wiese M ChemMedChem; 2013 Jan; 8(1):125-35. PubMed ID: 23150210 [TBL] [Abstract][Full Text] [Related]
2. Reversal of P-gp and BCRP-mediated MDR by tariquidar derivatives. Li XQ; Wang L; Lei Y; Hu T; Zhang FL; Cho CH; To KK Eur J Med Chem; 2015 Aug; 101():560-72. PubMed ID: 26197160 [TBL] [Abstract][Full Text] [Related]
3. HM30181 Derivatives as Novel Potent and Selective Inhibitors of the Breast Cancer Resistance Protein (BCRP/ABCG2). Köhler SC; Wiese M J Med Chem; 2015 May; 58(9):3910-21. PubMed ID: 25855895 [TBL] [Abstract][Full Text] [Related]
4. Scaffold identification of a new class of potent and selective BCRP inhibitors. Marighetti F; Steggemann K; Karbaum M; Wiese M ChemMedChem; 2015 Apr; 10(4):742-51. PubMed ID: 25735648 [TBL] [Abstract][Full Text] [Related]
5. Structure-activity relationships of new inhibitors of breast cancer resistance protein (ABCG2). Pick A; Müller H; Wiese M Bioorg Med Chem; 2008 Sep; 16(17):8224-36. PubMed ID: 18678495 [TBL] [Abstract][Full Text] [Related]
6. Potent and selective inhibitors of breast cancer resistance protein (ABCG2) derived from the p-glycoprotein (ABCB1) modulator tariquidar. Kühnle M; Egger M; Müller C; Mahringer A; Bernhardt G; Fricker G; König B; Buschauer A J Med Chem; 2009 Feb; 52(4):1190-7. PubMed ID: 19170519 [TBL] [Abstract][Full Text] [Related]
7. Flavonoids inhibit breast cancer resistance protein-mediated drug resistance: transporter specificity and structure-activity relationship. Katayama K; Masuyama K; Yoshioka S; Hasegawa H; Mitsuhashi J; Sugimoto Y Cancer Chemother Pharmacol; 2007 Nov; 60(6):789-97. PubMed ID: 17345086 [TBL] [Abstract][Full Text] [Related]
8. Specific inhibitors of the breast cancer resistance protein (BCRP). Pick A; Klinkhammer W; Wiese M ChemMedChem; 2010 Sep; 5(9):1498-505. PubMed ID: 20632361 [TBL] [Abstract][Full Text] [Related]
9. Investigation of chalcones and benzochalcones as inhibitors of breast cancer resistance protein. Juvale K; Pape VF; Wiese M Bioorg Med Chem; 2012 Jan; 20(1):346-55. PubMed ID: 22112540 [TBL] [Abstract][Full Text] [Related]
10. Modulation of P-glycoprotein but not MRP1- or BCRP-mediated drug resistance by LY335979. Shepard RL; Cao J; Starling JJ; Dantzig AH Int J Cancer; 2003 Jan; 103(1):121-5. PubMed ID: 12455064 [TBL] [Abstract][Full Text] [Related]
11. Discovery of alkoxyl biphenyl derivatives bearing dibenzo[c,e]azepine scaffold as potential dual inhibitors of P-glycoprotein and breast cancer resistance protein. Gu X; Tang X; Zhao Q; Peng H; Peng S; Zhang Y Bioorg Med Chem Lett; 2014 Aug; 24(15):3419-21. PubMed ID: 24928398 [TBL] [Abstract][Full Text] [Related]
12. Structure-activity relationships of flavonoids as inhibitors of breast cancer resistance protein (BCRP). Pick A; Müller H; Mayer R; Haenisch B; Pajeva IK; Weigt M; Bönisch H; Müller CE; Wiese M Bioorg Med Chem; 2011 Mar; 19(6):2090-102. PubMed ID: 21354800 [TBL] [Abstract][Full Text] [Related]
13. In vitro and in vivo evaluation of WK-X-34, a novel inhibitor of P-glycoprotein and BCRP, using radio imaging techniques. Jekerle V; Klinkhammer W; Scollard DA; Breitbach K; Reilly RM; Piquette-Miller M; Wiese M Int J Cancer; 2006 Jul; 119(2):414-22. PubMed ID: 16646006 [TBL] [Abstract][Full Text] [Related]
14. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Doyle L; Ross DD Oncogene; 2003 Oct; 22(47):7340-58. PubMed ID: 14576842 [TBL] [Abstract][Full Text] [Related]
15. Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2. Dai CL; Liang YJ; Wang YS; Tiwari AK; Yan YY; Wang F; Chen ZS; Tong XZ; Fu LW Cancer Lett; 2009 Jun; 279(1):74-83. PubMed ID: 19232821 [TBL] [Abstract][Full Text] [Related]
16. The "specific" P-glycoprotein inhibitor Tariquidar is also a substrate and an inhibitor for breast cancer resistance protein (BCRP/ABCG2). Kannan P; Telu S; Shukla S; Ambudkar SV; Pike VW; Halldin C; Gottesman MM; Innis RB; Hall MD ACS Chem Neurosci; 2011 Feb; 2(2):82-9. PubMed ID: 22778859 [TBL] [Abstract][Full Text] [Related]
17. Computational classification models for predicting the interaction of drugs with P-glycoprotein and breast cancer resistance protein. Erić S; Kalinić M; Ilić K; Zloh M SAR QSAR Environ Res; 2014; 25(12):939-66. PubMed ID: 25435255 [TBL] [Abstract][Full Text] [Related]
18. Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance. Nakamura Y; Oka M; Soda H; Shiozawa K; Yoshikawa M; Itoh A; Ikegami Y; Tsurutani J; Nakatomi K; Kitazaki T; Doi S; Yoshida H; Kohno S Cancer Res; 2005 Feb; 65(4):1541-6. PubMed ID: 15735043 [TBL] [Abstract][Full Text] [Related]
19. Marine natural products as breast cancer resistance protein inhibitors. Cherigo L; Lopez D; Martinez-Luis S Mar Drugs; 2015 Apr; 13(4):2010-29. PubMed ID: 25854646 [TBL] [Abstract][Full Text] [Related]
20. Novel structure-activity relationships and selectivity profiling of cage dimeric 1,4-dihydropyridines as multidrug resistance (MDR) modulators. Coburger C; Wollmann J; Krug M; Baumert C; Seifert M; Molnár J; Lage H; Hilgeroth A Bioorg Med Chem; 2010 Jul; 18(14):4983-90. PubMed ID: 20598550 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]